Psychosocial characteristics of individuals with non-stage IV melanoma

被引:73
|
作者
Trask, PC
Paterson, AG
Hayasaka, S
Dunn, RL
Riba, M
Johnson, T
机构
[1] Univ Michigan, Behav Med Program, Ann Arbor, MI 48108 USA
[2] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA
关键词
D O I
10.1200/JCO.2001.19.11.2844
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Melanoma is the fastest growing solid tumor among men and women and accounts for 79% of skin cancer-related deaths. Research has identified that distress is frequently associated with a diagnosis of cancer and may slow treatment-seeking and recovery, increasing morbidity and even mortality through faster disease course. Given that the 5-year survival rates for individuals with melanoma are determined primarily by the depth and extent of spread, distress that interferes with seeking treatment has the potential to be life-threatening. Patients and Methods: The current study was designed to identify levels of distress present in individuals seeking treatment at a large, Midwestern, multidisciplinary melanoma clinic. It also focused on determining the quality of life, level of anxiety, and coping strategies used by individuals with melanoma before treatment. Given that the course of treatment and outcome for patients with stage IV disease is vastly different from that of patients with stages I to III disease, they were excluded from the study. Results: Results indicated that most individuals who are presenting to a melanoma clinic do not report a clinically significant level of distress. However, there is some variability in this, with 29% of patients reporting moderate to high levels of distress. Moreover, analyses suggest that distressed individuals are more likely to use maladaptive coping strategies, such as escape-avoidance coping, and to have poorer quality of life. Conclusion: Although most individuals do not present with significant levels of distress, a significant minority are distressed and rely more heavily on coping strategies that do not benefit them. Such individuals would likely benefit most from psychological intervention.
引用
收藏
页码:2844 / 2850
页数:7
相关论文
共 50 条
  • [41] Stage IV Melanoma: Completely Resectable Patients are Scarce
    Wevers, K. P.
    Hoekstra, H. J.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S100 - S100
  • [42] Variates of survival for stage IV uveal melanoma.
    Rietschel, P
    Panageas, K
    Hanlon, C
    Patel, A
    Chapman, PB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 719S - 719S
  • [43] When to perform surgery in stage IV melanoma patients?
    de Wilt, Johannes H. W.
    Eggermont, Alexander M. M.
    ONKOLOGIE, 2008, 31 (05): : 226 - 227
  • [44] Palliative surgery for stage IV melanoma: Is it a primary treatment?
    Balch, CM
    ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (07) : 623 - 624
  • [45] Metastasectomy for Stage IV Melanoma: For Whom and How Much?
    Caudle, Abigail S.
    Ross, Merrick I.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 20 (01) : 133 - +
  • [46] Response of stage IV anal mucosal melanoma to chemotherapy
    Yeh, JJ
    Weiser, MR
    Shia, J
    Hwu, WJ
    LANCET ONCOLOGY, 2005, 6 (06): : 438 - 439
  • [47] Peripheral immune signatures and survival in stage IV melanoma
    Pawelec, Graham P.
    Martens, Alexander
    Garbe, Claus
    Weide, Benjamin
    Derhovanessian, Evelyna
    Schadendorf, Dirk
    Di Giacomo, Anna Maria
    Maio, Michele
    de Vries, Jolanda
    Zelba, Henning
    CANCER RESEARCH, 2014, 74 (19)
  • [48] Stage IV Melanoma: Completely Resectable Patients are Scarce
    K. P. Wevers
    H. J. Hoekstra
    Annals of Surgical Oncology, 2013, 20 : 2352 - 2356
  • [49] Special considerations for stage IV melanoma during pregnancy
    Beyeler, M
    Hafner, J
    Beinder, E
    Fauchêre, JC
    Stoeckli, SJ
    Fehr, M
    Dummer, R
    ARCHIVES OF DERMATOLOGY, 2005, 141 (09) : 1077 - 1079
  • [50] Ipilimumab as adjuvant Therapy in Patients with Melanoma Stage IV
    Schneiderbauer, R.
    Enk, A.
    Dimitrakopoulou-Strauss, A.
    Schulz, C.
    Hassel, J. C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 47 - 47